Director Bed & ISA Dealing

RNS Number : 6563K

IXICO plc

22 December 2022

 

22 December 2022

IXICO plc

("IXICO" or the "Company")

Director Bed & ISA Dealings

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience,announces that it received notification on 22 December 2022 that Grant Nash, CFO and PDMR, sold 200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and repurchased 200,000 Ordinary Shares into Mr Nash's ISA account.  Following this transaction Grant Nash's beneficial interest in the Companyshares has not changed.

Details of PDMR transaction

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Grant Nash
2	Reason for the notification
a)	Position/status	P DMR ( C FO )
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Sale and purchase of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			Sale at 25.00 p	200,000
			Purchase at 25.02 p	200,000
d)	Aggregated information
	- Aggregated volume	n/a
	- Price
e)	Date of the transactions	22 December 2022
f)	Place of the transaction	N/A

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)		[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

END

 

 

DSHLLLFLLLLFFBE